Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 10/20 | 0.80 |
| ▸ | MAPT | P10636 | 8/20 | 0.80 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.80 |
| ▸ | NPC1 | O15118 | 8/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.80 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.80 |
| ▸ | MEN1 | O00255 | 6/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.73 |
| ▸ | LMNA | P02545 | 2/20 | 0.73 |
| ▸ | TSHR | P16473 | 2/20 | 0.73 |
| ▸ | TP53 | P04637 | 4/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.71 |
| ▸ | HPGD | P15428 | 2/20 | 0.71 |
| ▸ | MAOA | P21397 | 2/20 | 0.71 |
| ▸ | MAOB | P27338 | 2/20 | 0.71 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1724568 | 0.94 | MAPT (0.85) | RAB9AMAPTSMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL10338453 | 0.90 | KDM4E (0.80) | RAB9AMAPTSMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL12238020 | 0.90 | RAB9A (0.80) | RAB9AMAPTSMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL4434901 | 0.89 | RAB9A (0.78) | RAB9AMAPTSMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL12289030 | 0.89 | RAB9A (0.78) | RAB9AMAPTSMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL2070406 | 0.89 | NPC1 (1.00) | RAB9AMAPTSMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL1038112 | 0.88 | MAPT (0.78) | RAB9AMAPTSMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL7499952 | 0.88 | MAPT (0.77) | RAB9AMAPTSMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL2069068 | 0.88 | MAPT (0.77) | RAB9AMAPTSMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL571576 | 0.88 | XDH (0.84) | RAB9AMAPTSMN1; SMN2NPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143588-A1 | Production of isoflavone derivatives | NOVOGEN RESEARCH PTY LTD. | 2005-06-30 | — | — | US | claimed |
| EP-1153020-A4 | PRODUCTION OF ISOFLAVONE DERIVATIVES | NOVOGEN RES PTY LTD (AU) | 2002-08-21 | — | — | EP | claimed |
| EP-1153020-A1 | PRODUCTION OF ISOFLAVONE DERIVATIVES | Novogen Research Pty. Ltd. (AU) | 2001-11-14 | — | — | EP | claimed |
| WO-2000049009-A1 | PRODUCTION OF ISOFLAVONE DERIVATIVES | NOVOGEN RESEARCH PTY. LTD. (AU) | 2000-08-24 | — | — | WO | claimed |
| CN-113512018-B | Flavonoid compound and preparation method and application thereof | 合肥工业大学 | 2023-07-18 | — | — | CN | disclosed |
| CN-113512018-A | Flavonoid compound and preparation method and application thereof | 合肥工业大学 | 2021-10-19 | — | — | CN | disclosed |
| US-7906660-B2 | Production of isoflavone derivatives | NOVOGEN RESEARCH PTY LTD (AU) | 2011-03-15 | — | — | US | disclosed |
| US-20060217564-A1 | Production of isoflavone derivatives | NOVOGEN RESEARCH PTY LTD. | 2006-09-28 | — | — | US | disclosed |
| US-20050143588-A1 | Production of isoflavone derivatives | NOVOGEN RESEARCH PTY LTD. | 2005-06-30 | — | — | US | disclosed |
| EP-1153020-A4 | PRODUCTION OF ISOFLAVONE DERIVATIVES | NOVOGEN RES PTY LTD (AU) | 2002-08-21 | — | — | EP | disclosed |
| EP-1153020-A1 | PRODUCTION OF ISOFLAVONE DERIVATIVES | Novogen Research Pty. Ltd. (AU) | 2001-11-14 | — | — | EP | disclosed |
| WO-2000049009-A1 | PRODUCTION OF ISOFLAVONE DERIVATIVES | NOVOGEN RESEARCH PTY. LTD. (AU) | 2000-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217564-A1 | Production of isoflavone derivatives | CYP51A1, EGLN2, EGLN3 | RAB9A 3050/4885MAPT 3761/4885SMN1; SMN2 3368/4885 |
| US-20050143588-A1 | Production of isoflavone derivatives | CYP51A1, EGLN2, EGLN3 | RAB9A 3050/4885MAPT 3761/4885SMN1; SMN2 3368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.